Articles

Mediation Effect of Body Mass Index on the Association Between Glycated Albumin and 10-year Atherosclerotic Cardiovascular Disease Risk

Cardiovascular diseases are global killers, and while HbA1c has been the go-to for glucose tracking, glycated albumin (GA) is the new, more reliable powerhouse set to revolutionize how we fight CVD.

Cardiovascular diseases (CVDs) represent the primary culprits behind deaths and disability worldwide, presenting a substantial risk to human health. This category of diseases encompasses coronary artery disease (CAD), stroke and myocardial infarction, which commonly arise due to arteriosclerosis, hypertension, hyperlipidaemia and diabetes.^1–5 Currently, glycated haemoglobin A1c (HbA1c) is recognised as a leading indicator in the clinical assessment of long-term blood glucose control.

Click here to access the article.